Vanguard Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,100,355 shares of CPRX stock, worth $158 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,100,355
Previous 7,980,661
1.5%
Holding current value
$158 Million
Previous $127 Million
1.37%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CPRX
# of Institutions
285Shares Held
96.6MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$366 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$179 Million2.97% of portfolio
-
State Street Corp Boston, MA6.03MShares$118 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$58.7 Million0.01% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.97MShares$58 Million0.12% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.01B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...